Dose-Escalation Safety and Pharmacokinetic Study of K305

Inclusion Criteria: * Male or female between 18 and 65 years of age * BMI between19 and 29 kg/m2 * Sufficiently healthy as determined by the investigator to receive the test medications and undergo the scheduled study procedure * Can breathe through both nostrils * Females of child-bearing potential must have a negative urine pregnancy test and must have been using adequate means of birth control for at least one month prior to study entry and during the study * Screening BP ≤ 140/90 * Screening SpO2 ≥ 96 * Can understand and sign the informed consent document * Can communicate with the investigator * Can understand and comply with the requirements of the protocol. Exclusion Criteria: * A clinically relevant history or presence of respiratory, thyroid, gastrointestinal, renal, hepatic, hematological, lymphatic, cardiovascular, psychiatric, neurologic, musculoskeletal, genitourinary, infective, inflammatory, immunological, dermatological, or connective tissue disease or disorder or a clinically relevant history or presence of narrow angle glaucoma and in men benign prostatic hypertrophy, Hashimoto"s Thyroiditis, lymphocytic thyroiditis, or uncontrolled diabetes * Clinically significant abnormalities in laboratory values * Clinically relevant sinus/nasal surgical history * Current condition, such as nasal congestion or sinus infection, that may influence responses to study medication * History of recurrent nose bleeds * History of pseudocholinesterase deficiency or previous prolonged paralysis with succinylcholine or "difficulty waking up from general anesthesia" * Allergic to or intolerant of tetracaine, benzocaine, other ester local anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreens) * Allergic to or intolerant of oxymetazoline or preservatives found in these solutions * History of alcoholism and/or drug abuse * Have taken a monamine oxidase inhibitor, or vasopressor drug within the past 3 weeks * Have received or taken local anesthetics within 72 hours of the first or second treatment visits * Are nursing, pregnant, suspected of being pregnant, or trying to become pregnant (Females will be required to take a urine pregnancy test at each study visit to rule out pregnancy) * Have used any investigational drug and/or participated in any clinical trial within 30 days of baseline